{"schema_version":"secwatch.filing_event.v1","accession":"0001420800-23-000012","form_type":"8-K","ticker":"ENOV","cik":"0001420800","company_name":"Enovis CORP","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.796616+00:00","generated_at":"2026-06-15T21:32:04.672265+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Enovis Q1 net sales $406M (+9% organic), adj EPS $0.44; raises FY2023 outlook","bullets":["Recon segment organic growth 19% (P&R +4%); total organic sales +9%.","Adjusted EBITDA $56M (13.9% of sales, +120 bps YoY); net loss from cont ops $0.42/sh.","FY 2023 outlook raised: organic rev growth 6-7% (prev 5-6%), adj EBITDA $259-267M, adj EPS $2.18-2.32.","Agreement to acquire Novastep (bunion segment) expected to close Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001420800-23-000012","json":"https://secwatch.observer/filing/0001420800-23-000012.json","markdown":"https://secwatch.observer/filing/0001420800-23-000012.md","text":"https://secwatch.observer/filing/0001420800-23-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420800/000142080023000012/0001420800-23-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420800/000142080023000012/cfx-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T21:32:04.672265+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9dcbc133f18ebe2a6328174872ac321c0a2d23b7","claim":"Enovis CORP reported first quarter ended March 31, 2023 results: revenue $406 million, net income net loss from continuing operations of $23 million, EPS adjusted earnings per share of $0.44. Guidance raised.","evidence_excerpt":"will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. First Quarter 2023 Financial Results Enovis’ first quarter net sales of $406 million grew 8% from the prior year quarter, including 9% organic growth and a 1.5% currency headwind. Sales in the Reconstructive segment grew 19%, both as reported and organically, and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420800/000142080023000012/0001420800-23-000012-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$406 million"},{"label":"Net income","value":"net loss from continuing operations of $23 million"},{"label":"EPS","value":"adjusted earnings per share of $0.44"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}